/PRNewswire/ Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and.
/PRNewswire/ Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and.
/PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare.
Dynacure announces publication of Hierarchical Bayesian modelling of disease progression in Orphanet Journal of Rare Diseases
Bayesian statistical approach based on natural history study could address clinical trial design challenges in centronuclear myopathy
News provided by
Share this article
Share this article
STRASBOURG, France and PHILADELPHIA, Jan. 15, 2021 /PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced the publication of a paper entitled,
Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy (CNM). The paper was published this month in Orphanet Journal of Rare Diseases, a scientific, peer-reviewed publication and can be accessed here.